tiprankstipranks
Can-Fite BioPharma (CANF)
XASE:CANF
US Market

Can-Fite BioPharma (CANF) Stock Forecast & Price Target

652 Followers
See the Price Targets and Ratings of:

CANF Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Can-Fite
BioPharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CANF Stock 12 Month Forecast

There Are No Analyst Ratings for CANF In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

CANF Financial Forecast

CANF Earnings Forecast

The previous quarter’s earnings for CANF were -$0.13.
The previous quarter’s earnings for CANF were -$0.13.

CANF Sales Forecast

The previous quarter’s earnings for CANF were $204.19K.
The previous quarter’s earnings for CANF were $204.19K.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
D. Boral Capital Analyst forecast on CANF
D. Boral Capital
D. Boral Capital
Hold
Downgraded
12/24/25
Can-Fite BioPharma downgraded to Hold from Buy at D. Boral CapitalCan-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital
H.C. Wainwright Analyst forecast on CANF
H.C. Wainwright
H.C. Wainwright
$2.5
Buy
-38.12%
Downside
Initiated
11/04/25
Buy Rating for Can-Fite BioPharma: Promising A3AR Agonists in Psoriasis and Liver Cancer with Strong Safety Profile
Alliance Global Partners Analyst forecast on CANF
Alliance Global Partners
Alliance Global Partners
$12$4.5
Buy
11.39%
Upside
Reiterated
04/15/25
Can-Fite price target lowered to $4.50 from $12 at Alliance Global PartnersCan-Fite price target lowered to $4.50 from $12 at Alliance Global Partners
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
D. Boral Capital Analyst forecast on CANF
D. Boral Capital
D. Boral Capital
Hold
Downgraded
12/24/25
Can-Fite BioPharma downgraded to Hold from Buy at D. Boral CapitalCan-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital
H.C. Wainwright Analyst forecast on CANF
H.C. Wainwright
H.C. Wainwright
$2.5
Buy
-38.12%
Downside
Initiated
11/04/25
Buy Rating for Can-Fite BioPharma: Promising A3AR Agonists in Psoriasis and Liver Cancer with Strong Safety Profile
Alliance Global Partners Analyst forecast on CANF
Alliance Global Partners
Alliance Global Partners
$12$4.5
Buy
11.39%
Upside
Reiterated
04/15/25
Can-Fite price target lowered to $4.50 from $12 at Alliance Global PartnersCan-Fite price target lowered to $4.50 from $12 at Alliance Global Partners
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Can-Fite BioPharma

3 Months
xxx
Success Rate
2/2 ratings generated profit
100%
Average Return
+32.90%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +32.90% per trade.
1 Year
DeepSeek BiotechnologyTipRanks - DeepSeek
Success Rate
2/2 ratings generated profit
100%
Average Return
+39.40%
Copying DeepSeek Biotechnology's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +39.40% per trade.
2 Years
xxx
Success Rate
2/2 ratings generated profit
100%
Average Return
+39.40%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +39.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CANF Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
1
1
0
0
0
Hold
1
1
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
2
1
0
0
In the current month, CANF has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CANF average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

CANF Stock Forecast FAQ

What is CANF’s average 12-month price target, according to analysts?
Currently, no data Available
What is CANF’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CANF, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is CANF a Buy, Sell or Hold?
      Currently, no data Available
      What is Can-Fite BioPharma’s price target?
      Currently, no data Available
      What do analysts say about Can-Fite BioPharma?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of CANF?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.